SUPERNUS PHARMACEUTICALS, INC. Acquisitions, Net of Cash Acquired
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Acquisitions, Net of Cash Acquired of $293.09 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2026-03-02
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2025-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2024-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2022-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2022-09-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2025 was $293.09M.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2024 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2023 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $293.09M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | $293.09M 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 10-K · filed 2023-03-09 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $950.00K 10-K · filed 2023-03-09 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $950.00K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $950.00K 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.34M derived: sum of 2 quarters · filed 2023-03-09 | $298.54M 10-K · filed 2023-03-09 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $297.20M 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $297.20M 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-13 | $0.00 derived: sum of 2 quarters · filed 2022-04-13 | $0.00 10-K · filed 2022-04-13 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-17 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |